R. A. Cherny, C. S. Atwood, M. E. Xilinas, D. N. Gray, W. D. Jones, C. A. Mclean, K. J. Barnham, I. Volitakis, F. W. Fraser, Y. S. Kim, X. Huang, L. E. Goldstein, R. D. Moir, J. T. Lim, K. Beyreuther, H. Zheng, R. E. Tanzi, C. L. Masters and A. I. Bush, “Treatment with Copper-Zinc Chelator Markedly and Rapidly Inhibits B-Amyloid Accumulation In Alzheimer’s Disease Transgenic Mice,” Neurology, Vol. 30, No. 3, 2001, pp. 665-676.

has been cited by the following article:

• TITLE: The Functions of the Amyloid Precursor Protein Gene and Its Derivative Peptides: III Pharmacological Studies

  AUTHORS: Peter K. Panegyres, Emily R. Atkins

  KEYWORDS: Amyloid Precursor Protein, APP, Genes, Dementia, Alzheimer’s Disease

  JOURNAL NAME: Neuroscience and Medicine, Vol.2 No.4, December 2, 2011

  ABSTRACT: Pharmacological studies reveal APP and Aβ have interactions with glutamate and calcium, cytokines, copper/zinc chelators, secretases and presenilins, nicotinic receptors, acetycholinesterase, neurotrophins, non-steroidal anti-inflame-matory drugs, monoclonal antibodies to Aβ, protease inhibitors, oestrogen, homocysteine, immediate early genes such as c-fos or c-jun and cholesterol. These functional and pharmacological observations highlight the need for greater understanding of APP and Aβ in brain function and have implications for clinical trials.